We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+10.92%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$43.9B
AUM Growth
+$2.87B
(+7%)
Cap. Flow
-$890M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
13.25%
Holding
2,343
New
170
Increased
997
Reduced
1,015
Closed
150
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$111M |
| 2 |
Verizon
VZ
|
+$103M |
| 3 |
AT&T
T
|
+$103M |
| 4 |
Kroger
KR
|
+$97.1M |
| 5 |
3M
MMM
|
+$92.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$138M |
| 2 |
Tesla
TSLA
|
+$110M |
| 3 |
JPMorgan Chase
JPM
|
+$103M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$89.4M |
| 5 |
Apple
AAPL
|
+$85.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 16.25% |
| 3 | Financials | 11.85% |
| 4 | Industrials | 11.44% |
| 5 | Consumer Discretionary | 10.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
576
PBF Energy
PBF
$8.18B
| $13.4M | 0.03% |
327,475
+1,561
| +0.5% | +$64.9K |
|
577
EPAM Systems
EPAM
$5.15B
| $13.4M | 0.03% |
41,327
-16,791
| -29% | -$5.71M |
|
578
Hanover Insurance
THG
$7.8B
| $13.3M | 0.03% |
98,368
-7,854
| -7% | -$1.1M |
|
579
EnerSys
ENS
$6.8B
| $13.3M | 0.03% |
180,207
-27,767
| -13% | -$1.94M |
|
580
Targa Resources
TRGP
$57.2B
| $13.2M | 0.03% |
180,106
-101,269
| -36% | -$7.07M |
|
581
Nike
NKE
$61.3B
| $13.2M | 0.03% |
112,939
-119,167
| -51% | -$12M |
|
|
FL
582
DELISTED
Foot Locker
FL
| $13.2M | 0.03% |
355,295
+55,218
| +18% | +$1.89M |
|
583
KE Holdings
BEKE
$18.7B
| $13.1M | 0.03% |
941,701
+94,012
| +11% | +$1.31M |
|
584
S&P Global
SPGI
$120B
| $13.1M | 0.03% |
39,256
-11,242
| -22% | -$3.71M |
|
585
L3Harris
LHX
$53.3B
| $13M | 0.03% |
63,208
+29,263
| +86% | +$6.6M |
|
586
Lithia Motors
LAD
$8.39B
| $13M | 0.03% |
64,834
-26,444
| -29% | -$5.65M |
|
587
CoStar Group
CSGP
$12.7B
| $12.8M | 0.03% |
166,427
-8,661
| -5% | -$677K |
|
588
Live Nation Entertainment
LYV
$43B
| $12.7M | 0.03% |
183,118
+154,892
| +549% | +$11.5M |
|
589
Neurocrine Biosciences
NBIX
$16.5B
| $12.7M | 0.03% |
106,535
-7,068
| -6% | -$828K |
|
590
DaVita
DVA
$11.5B
| $12.6M | 0.03% |
168,474
+150,201
| +822% | +$11.7M |
|
591
Exelon
EXC
$46.2B
| $12.6M | 0.03% |
290,950
-257,133
| -47% | -$10.2M |
|
592
Ashland
ASH
$3.44B
| $12.5M | 0.03% |
116,574
+73,503
| +171% | +$7.75M |
|
593
Gerdau
GGB
$9.25B
| $12.5M | 0.03% |
2,841,740
-3,137,887
| -52% | -$13.5M |
|
594
Dana Inc
DAN
$3.25B
| $12.5M | 0.03% |
826,075
+133,002
| +19% | +$2.06M |
|
595
Royal Gold
RGLD
$19.8B
| $12.3M | 0.03% |
110,003
-38,935
| -26% | -$4.01M |
|
596
United Airlines
UAL
$41.1B
| $12.3M | 0.03% |
327,589
+127,315
| +64% | +$5.17M |
|
597
Charles River Laboratories
CRL
$13.4B
| $12.3M | 0.03% |
56,557
-53,472
| -49% | -$11.7M |
|
598
Infosys
INFY
$51B
| $12.3M | 0.03% |
683,173
-159,514
| -19% | -$2.97M |
|
599
Huazhu Hotels Group
HTHT
$12.8B
| $12.2M | 0.03% |
288,648
-13,693
| -5% | -$495K |
|
600
Marvell Technology
MRVL
$190B
| $12.1M | 0.03% |
336,142
+133,893
| +66% | +$5.47M |
|
Similar funds
VGA
AQR Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, AQR Capital Management held 2,343 positions worth $43.9B, up 7% from $41B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
AQR Capital Management's Q4 2022 filing shows 170 new, 997 increased, 1,015 reduced and 150 closed positions. Its largest new stake was Generac Holdings: 310,080 shares worth $30.5M. The largest sale was Gilead Sciences, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q4 2022 buy was Generac Holdings: 310,080 shares worth $30.5M.
- AQR Capital Management added most to Humana in Q4 2022, an estimated $111M increase.
- AQR Capital Management's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $138M.
- AQR Capital Management fully exited Abiomed Inc in Q4 2022, selling an estimated $22.4M.
- AQR Capital Management's ten largest holdings make up 13% of its $43.9B portfolio in Q4 2022.
- AQR Capital Management opened 170 new positions and closed 150 in Q4 2022.
- AQR Capital Management's portfolio value rose 7% quarter-over-quarter to $43.9B.
Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.